voluble
发表于 2025-3-25 03:38:34
http://reply.papertrans.cn/83/8285/828452/828452_21.png
bronchiole
发表于 2025-3-25 08:24:24
http://reply.papertrans.cn/83/8285/828452/828452_22.png
相容
发表于 2025-3-25 15:09:16
http://reply.papertrans.cn/83/8285/828452/828452_23.png
债务
发表于 2025-3-25 16:34:00
http://reply.papertrans.cn/83/8285/828452/828452_24.png
助记
发表于 2025-3-25 20:14:56
Resistance to Targeted Anti-Cancer Therapeuticshttp://image.papertrans.cn/r/image/828452.jpg
Connotation
发表于 2025-3-26 00:37:22
https://doi.org/10.1007/978-1-4614-7654-2Rituximab; antibody-drug conjugates; cancer drug resistance; mABs; monoclonal antibody; antibodies
马具
发表于 2025-3-26 08:13:49
978-1-4899-8732-7Springer Science+Business Media New York 2013
neutrophils
发表于 2025-3-26 10:13:23
Resistance to Immunotherapeutic Antibodies in Cancer978-1-4614-7654-2Series ISSN 2196-5501 Series E-ISSN 2196-551X
impale
发表于 2025-3-26 16:15:53
2196-5501 etic mechanisms of resistance by various mAbs.Covers the potThe traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encourag
赔偿
发表于 2025-3-26 19:14:17
Resistance to Anticancer Antibodies: From Mechanisms to Solutions,f resistance to monoclonal antibody therapy. In this review, we discuss the available data for three of the best described antibodies, rituximab, trastuzumab and cetuximab. A variety of approaches and strategies has been suggested or are currently being tested to circumvent resistance to these antibodies.